Cetuximab for Squamous Cell Carcinoma of the Head and Neck
Author(s):
Article Type:
Review Article (دارای رتبه معتبر)
Abstract:
Context: Treatment outcome for locally advanced squamous cell carcinoma of the head and neck is poor. Recently, anti-epidermal growth factor monoclonal antibodies, such as cetuximab have been used to improve outcome.
Evidence Acquisition: Medline, EMBASE, and SCOPUS were searched to identify published studies that evaluated cetuximab for loco regionally advanced and metastatic/recurrent squamous cell carcinoma of head and neck. Only published studies in English between 1990 and 2016 were included.
Evidence Acquisition: Medline, EMBASE, and SCOPUS were searched to identify published studies that evaluated cetuximab for loco regionally advanced and metastatic/recurrent squamous cell carcinoma of head and neck. Only published studies in English between 1990 and 2016 were included.
Results
Cetuximab may be administered concomitantly with radiation alone or in combination with chemotherapy during the induction phase of sequential modalities. Also, it has been used in combination with chemotherapy as first line or second line for treatment of metastatic/recurrent patients.Conclusions
Cetuximab can be incorporated at some points in the course of treatment of patients with squamous cell carcinoma of the head and neck. The best protocols and the appropriate patients remain to be defined.Keywords:
Language:
English
Published:
International Journal of Cancer Management, Volume:10 Issue: 11, Nov 2017
Page:
2
magiran.com/p1790864
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یکساله به مبلغ 1,390,000ريال میتوانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.
In order to view content subscription is required
Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!